Top Page
AnteoTech Ltd
(Sydney:ADO)
AnteoTech Ltd (ADO) vs. iShares MSCI Australia ETF (EWA)
AnteoTech Ltd Business Overview & Revenue Model
AnteoTech Ltd Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -995.80K | 968.88K | 460.40K | 365.72K | 760.88K | 898.07K |
| Gross Profit | -1.55M | 968.88K | 460.40K | 365.72K | 760.88K | 898.07K |
| EBITDA | -5.66M | -7.96M | -11.57M | -12.35M | -12.07M | -7.18M |
| Net Income | -3.69M | -6.76M | -8.88M | -12.65M | -10.72M | -6.22M |
Balance Sheet | ||||||
| Total Assets | 4.85M | 6.45M | 9.38M | 5.36M | 15.26M | 23.68M |
| Cash, Cash Equivalents and Short-Term Investments | 1.44M | 2.34M | 5.03M | 2.72M | 10.10M | 21.39M |
| Total Debt | 2.85M | 1.96M | 2.31M | 1.31M | 1.03M | 1.28M |
| Total Liabilities | 2.82M | 3.30M | 4.08M | 2.99M | 2.91M | 2.56M |
| Stockholders Equity | 2.03M | 3.15M | 5.31M | 2.38M | 12.36M | 21.11M |
Cash Flow | ||||||
| Free Cash Flow | -2.90M | -6.05M | -7.58M | -8.77M | -11.77M | -4.76M |
| Operating Cash Flow | -2.82M | -5.83M | -6.52M | -8.08M | -8.65M | -4.55M |
| Investing Cash Flow | -118.14K | -174.87K | -1.06M | -690.83K | -3.12M | -213.07K |
| Financing Cash Flow | -704.07K | 3.32M | 9.89M | 1.39M | 482.29K | 22.94M |
AnteoTech Ltd Technical Analysis
AnteoTech Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$86.67M | -9.92 | -138.54% | ― | ― | 16.61% | |
53 Neutral | AU$193.16M | -59.74 | -41.51% | ― | -40.74% | -21.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$71.50M | -6.80 | -49.72% | ― | ― | 10.78% | |
48 Neutral | AU$33.06M | -7.14 | -143.71% | ― | 306.88% | ― | |
41 Neutral | AU$56.16M | -5.40 | -71.87% | ― | 7.65% | -19.13% | |
40 Underperform | AU$35.68M | -5.45 | -159.86% | ― | 110.44% | 35.90% |
AnteoTech Ltd Corporate Events
AnteoTech Ltd has released its interim financial report for the half year ended 31 December 2025, detailing a sharp fall in reported revenue from ordinary activities alongside a narrower loss. Revenue from ordinary activities declined 85% to $97,000, largely due to timing of sales under a five-year US$1.8 million supply agreement with Serum Institute of India, while total revenue and other income fell 15% to $2.7 million and the net loss narrowed 36% to $1.4 million.
Excluding Serum Institute of India, sales to other customers rose 6%, indicating underlying demand growth despite headline revenue volatility linked to contract timing. The group paid no dividend, and net tangible assets per share dropped to 0.07 cents from 0.28 cents, underscoring continued balance-sheet pressure even as losses moderate and the company works to commercialise its battery and life sciences technologies.
The most recent analyst rating on (AU:ADO) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.
AnteoTech Ltd has lodged an updated Appendix 3H notification concerning the cessation of certain securities, specifically correcting an error in the previously reported cessation date for its ADOAAD options. The clarification ensures the company’s issued capital records are accurate, helping maintain transparency for shareholders and the market regarding the status and timing of its listed options.
The updated notice replaces a prior announcement made earlier on 9 February 2026 and confirms that the original cessation date disclosed was incorrect. By promptly amending this administrative detail, AnteoTech reduces potential confusion around its capital instruments and reinforces compliance with ASX disclosure requirements, though the change does not signal any broader strategic or operational shift.
The most recent analyst rating on (AU:ADO) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.
AnteoTech Ltd has announced the cessation of two series of options, with a total of 11,475,000 securities lapsing after the conditions attached to these instruments were not, or could no longer be, satisfied. The affected options, which were due to expire in November 2027 and August 2029 at exercise prices of $0.048 and $0.0375 respectively, will no longer be part of the company’s potential capital base, slightly simplifying its capital structure and removing a source of potential future dilution for shareholders.
The most recent analyst rating on (AU:ADO) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.
AnteoTech Ltd has announced the issue of 138,206,230 unlisted options with an exercise price of 3.5 cents and an expiry date of 31 January 2028. The options, which form part of a previously flagged transaction and are not intended to be quoted on the ASX, represent a significant potential source of future equity and may dilute existing shareholders if exercised, while providing the company with additional capital-raising flexibility.
The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.
AnteoTech has issued 245.7 million new shares and 138.2 million listed options under its 27 January placement, with the securities released without a prospectus under section 708A and accompanied by confirmation of ongoing Corporations Act compliance and absence of excluded information; the cleansing notice clears the way for secondary trading, signalling continued execution of the company’s capital-raising plans to support its advanced materials strategy.
The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.
AnteoTech’s latest quarterly update highlights a strategic push to expand its sales pipeline and enter new markets through joint development and sales partnerships, alongside a strengthened balance sheet following a A$3.5 million capital raise completed in January 2026. In advanced battery technologies, the company signed a Joint Development and Sales Agreement with US-based Black Diamond Structures for a combined Anteo X™/Molecular Rebar™ CNT dispersion product with customer trials beginning in February, achieved a tenfold scale-up of Ultranode™ anode material for Wyon AG’s commercial cell evaluations, hit a new Ultranode™ X performance milestone of more than 1,000 cycles at 80% capacity retention, dispatched global samples of its new Anteo S separator, and is negotiating two Ultranode™ 95 JDAs with battery manufacturers supplying the US defence drone sector and other markets. In life sciences, AnteoTech secured a US$185,000 AnteoBind™ order from Serum Institute of India, gained additional Japanese sales, initiated evaluations of AnteoBind™-activated ELISA plates and a potential CLIA product development program with a major global life sciences company, and generated comparative data showing its AnteoBind™ NXT chemistry can cut antibody usage sixfold versus Tosyl chemistry while reducing non-specific binding. The company ended the quarter with A$1.4 million cash and no debt, and a pro-forma A$4.9 million post-raise, which it expects—together with revenue and an R&D rebate—to fund operations through calendar 2026, while it restructures its finance leadership and intensifies efforts to convert its expanded opportunity pipeline into sales across both its battery and diagnostics businesses.
The most recent analyst rating on (AU:ADO) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.
AnteoTech Limited has appointed Scott Waddell as interim chief financial officer and company secretary, effective 2 February 2026, bringing three decades of corporate finance experience across multiple resource companies to the Brisbane-based advanced materials specialist. Waddell’s extensive background in leading finance teams, overseeing global finance and governance functions, and managing business development and M&A activities is expected to bolster AnteoTech’s financial stewardship and corporate governance as it continues to commercialise its battery and life sciences technologies in competitive global markets.
The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.
AnteoTech Ltd has announced a proposed issue of securities via a placement, comprising a maximum of 15,356,249 new unlisted options with an exercise price of 3.5 cents and an expiry date of 31 January 2028, along with 15,356,249 options under existing code ADOO expiring 31 May 2026. The issuance, scheduled for 3 February 2026, is designed to expand the company’s option pool and may provide additional future capital if exercised, potentially affecting the capital structure and dilution for existing shareholders while supporting the company’s funding flexibility on the ASX.
The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.
AnteoTech Ltd has announced a proposed placement or similar issue of up to 245,699,993 ordinary fully paid shares and 245,699,992 options, comprising 122,849,996 new unlisted options with a 3.5 cent exercise price expiring 31 January 2028 and 122,849,996 options expiring 31 May 2026. The issue, scheduled for 3 February 2026, represents a significant capital-raising and balance sheet initiative that will expand the company’s securities on issue, with potential dilution for existing shareholders but added optionality and future funding flexibility for the company as it pursues its strategic and operational objectives.
The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.
AnteoTech Ltd has raised A$3.5 million via a discounted share placement to institutional and professional investors, boosting its pro-forma cash balance to A$6.6 million and issuing free attaching listed and unlisted options as part of the offer. The funds will be used to accelerate the global commercialisation of its Life Sciences and Advanced Battery Technology products, support revenue growth initiatives, and advance strategic partnerships, including converting current customer trials into commercial supply agreements, entering the US market with a joint battery product developed with Black Diamond Structures, progressing EV-sector discussions around its Ultranode X technology, and driving new diagnostics customer wins and product development, particularly in India.
The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.
AnteoTech Ltd has requested and been granted a trading halt on its shares by the ASX, effective from 22 January 2026, while it prepares a market announcement regarding a material capital raising. The halt will remain in place until either the company releases the capital-raising announcement or normal trading resumes on 27 January 2026, signalling that AnteoTech is moving to secure significant new funding, which could have implications for its capital structure and existing shareholders once details are disclosed.
The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.
AnteoTech has reported six‑month strategic progress for its Advanced Battery Technologies unit, highlighting rising commercial traction for its Ultranode™ 95 high‑silicon anode technology in the drone and defence sectors, with two non‑exclusive joint development agreements under negotiation with US‑ and Europe‑focused drone battery manufacturers. The company is expanding global sampling and validation of Ultranode™ 95 and Anteo X™ in the unmanned aerial systems market, responding to growing customer demand across the US, South Korea and Europe, while also launching its new Anteo S separator coating, completing a co‑developed carbon nanotube dispersion product with Black Diamond Structures ahead of customer trials, and advancing Ultranode™ 70 testing with Wyon AG—moves that collectively deepen its multi‑product pipeline and position AnteoTech to convert technical evaluations into commercial agreements in a rapidly growing drone battery market.
The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.
AnteoTech Ltd has announced the resignation of Andrew Cook from his dual roles as Chief Financial Officer and Company Secretary, as he departs to pursue other business interests. The board has commenced a process to identify his successor and has committed to an orderly transition under his existing employment terms, with further updates on interim and permanent arrangements to follow, signalling a period of financial and governance reshaping that stakeholders will watch closely given his central role in the company’s corporate and reporting functions.
The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.
AnteoTech has secured a US$185,000 AnteoBind order from the Serum Institute of India under its five-year supply agreement, with shipment set for early January 2026, while simultaneously deepening the relationship through SII’s evaluation of a new AnteoBind-activated ELISA plate prototype targeting a market that accounts for roughly 40% of the global immunoassay segment. The company reports growing momentum in its Life Sciences business, including approximately AU$70,000 in new sales to Japanese customers, a sharp increase in AnteoBind NXT evaluations across major global markets, re-engagement with large life sciences players on joint CLIA and ELISA product development, and a strategic shift from additive supplier to core-ingredient provider, supported by recent peer-reviewed publications and expanded commercial activity in India, positioning AnteoTech to tap into the sizeable and fast-growing CLIA and ELISA markets in 2026 and beyond.
The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.
AnteoTech Ltd has presented an update on its business activities, specifically highlighting advancements in maximizing high silicon anode performance. This development is significant for the company as it could enhance its position in the energy storage sector, potentially leading to improved operational efficiencies and market competitiveness.
The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.
AnteoTech Ltd has announced a change in the interests of its director, Glenda McLoughlin, involving the acquisition of 7,500,000 unlisted options and the expiry of 5,000,000 unlisted options. This adjustment in the director’s securities holdings reflects ongoing strategic decisions within the company, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.
AnteoTech Ltd has announced the issuance of 42.5 million unquoted options, exercisable at $0.0375, with expiration dates in 2028 and 2029. This strategic move could potentially enhance the company’s financial flexibility and strengthen its market position by providing additional capital for growth and development.
The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.